Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.